Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 14Phase 3 6Phase 1/2 5Phase EARLY_PHASE1 1

Status

Active not recruiting 4Completed 2

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Endocrine 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Hereditary Sensory and Autonomic Neuropathies 1Advanced HER2+Breast Cancer 1

Interventions

Cyclophosphamide 149Docetaxel 138Paclitaxel 127Trastuzumab 119Tamoxifen 110Capecitabine 104Letrozole 92Epirubicin 79Doxorubicin 70Anastrozole 70exemestane 67Fulvestrant 65Fluorouracil 61Radiotherapy 60pertuzumab 40Gemcitabine 39Carboplatin 38Vinorelbine 34Goserelin 34Bevacizumab 29Zoledronic Acid 28Methotrexate 28Chemotherapy, Adjuvant 28eribulin 27Lapatinib 25ribociclib 24palbociclib 24Drug Therapy 22130-nm albumin-bound paclitaxel 20pegfilgrastim 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Breast Neoplasms × Alpelisib × Clear all
NCT05646862 2026-05-06

INAVO121

Hoffmann-La Roche

Phase 3 Active not recruiting
420 enrolled
Breast

Breast Neoplasms

NCT05038735 2026-04-08

EPIK-B5

Novartis

Phase 3 Active not recruiting
234 enrolled
Breast

Breast Neoplasms

NCT05501886 2026-02-10

VIKTORIA-1

Celcuity Inc

Phase 3 Active not recruiting
701 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05063786 2025-09-08

ALPHABET

Spanish Breast Cancer Research Group

Phase 3 Active not recruiting
27 enrolled
Breast

Breast Neoplasms

NCT02437318 2025-02-13

SOLAR-1

Novartis

Phase 3 Completed
572 enrolled 22 charts 1 FDA
BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT03439046 2024-08-01

BioItaLEE

Novartis

Phase 3 Completed
287 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡